Sign In
Buy ADILW
$0.0009
+0 (+0%)
At Close: Oct 26, 2023
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
02:00pm, Wednesday, 08'th Mar 2023 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on d
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
09:19pm, Monday, 06'th Mar 2023 GlobeNewswire Inc.
Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities
Adial Pharmaceuticals Schedules Business Update Conference Call
02:00pm, Thursday, 02'nd Mar 2023 GlobeNewswire Inc.
Management to provide an update on its regulatory and partnering strategy for the United States and Europe Management to provide an update on its regulatory and partnering strategy for the United Stat
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
12:00pm, Friday, 24'th Feb 2023 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on de
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
08:30pm, Monday, 22'nd Aug 2022 GlobeNewswire Inc.
Kevin Schuyler appointed Chairman of Adial’s Board
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
01:15pm, Tuesday, 16'th Aug 2022 GlobeNewswire Inc.
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
01:25pm, Monday, 18'th Jul 2022 GlobeNewswire Inc.
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
03:49pm, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders fr
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
01:16pm, Monday, 27'th Jun 2022 GlobeNewswire Inc.
Expects Release of Top-Line Data in July Expects Release of Top-Line Data in July
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
02:48pm, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
New patent covers the use of the full genetic panel measuring all five genetic biomarkers New patent covers the use of the full genetic panel measuring all five genetic biomarkers
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
01:25pm, Thursday, 19'th May 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company fo
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
01:25pm, Monday, 16'th May 2022 GlobeNewswire Inc.
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
01:15pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company fo
Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th
01:15pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on d
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
02:15pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on de
